Metaanalyses—highest level of empirical evidence? Wolfgang MaierHans-Jürgen Möller EDITORIAL Pages: 369 - 370
Are the new antipsychotics no better than the classical neuroleptics? Hans-Jürgen Möller EDITORIAL Pages: 371 - 372
Executive function improvement upon remission of recurrent unipolar depression E. BiringerA. LundervoldA. Lund ORIGINAL PAPER 01 April 2005 Pages: 373 - 380
Effect of treatment on serum brain–derived neurotrophic factor levels in depressed patients A. Saffet GonulF. AkdenizS. Vahip ORIGINAL PAPER 06 April 2005 Pages: 381 - 386
Is dose escalation of antidepressants a rational strategy after a medium–dose treatment has failed? M. AdliCh. BaethgeM. Bauer ORIGINAL PAPER 29 April 2005 Pages: 387 - 400
Volume deficits of subcortical nuclei in mood disorders H. BielauK. TrübnerB. Baumann ORIGINAL PAPER 17 August 2005 Pages: 401 - 412
Intact and deficient feature fusion in schizophrenia A. BrandS. KopmannM. H. Herzog ORIGINAL PAPER 04 May 2005 Pages: 413 - 418
Two types of classification for male opioid dependence: Identification of an opioid addict with depressive features J. ModestinB. MatutatO. Würmle ORIGINAL PAPER 29 April 2005 Pages: 419 - 427
Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD J. KrauseCh. la FougereSt. H. Dresel ORIGINAL PAPER 17 August 2005 Pages: 428 - 431
Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms M. RiedelN. MüllerH.–J. Möller ORIGINAL PAPER 04 November 2005 Pages: 432 - 437
Proteomic analysis of the CSF in unmedicated patients with major depressive disorder reveals alterations in suicide attempters J. BrunnerTh. BronischC. W. Turck SHORT COMMUNICATION Pages: 438 - 440
